Caprelsa
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Medullary Thyroid Cancer
Conditions
Metastatic Medullary Thyroid Cancer
Trial Timeline
Apr 1, 2014 → Jun 1, 2015
NCT ID
NCT02109250About Caprelsa
Caprelsa is a pre-clinical stage product being developed by Sanofi for Metastatic Medullary Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02109250. Target conditions include Metastatic Medullary Thyroid Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Medullary Thyroid Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02109250 | Pre-clinical | Completed |
Competing Products
20 competing products in Metastatic Medullary Thyroid Cancer